🦴 #BoneHealth in newly diagnosed female #BreastCancer patients in China 🇨🇳

❗ 63.2% have Abnormal Bone Mass
🔺 92.3% with Vitamin D deficiency
⚠️ 5.5x ⬆️ risk of ABM in BC 🆚 controls
🧑‍⚕️ Young BC patients (<45) 9x higher risk

@oncoalert.bsky.social @nature.com

👉 nature.com/articles/s41598-024-84698-1

Urinary DNA methylation test:

✅89% sensitivity for high-grade or invasive #BladderCancer‼️
✅Outperforms NMP22 & urine cytology tests with high specificity
✅Excellent negative predictive value
🔽Suboptimal positive predictive value

@oncoalert.bsky.social

jamanetwork.com/journals/jam...

💫 Phase 3 #KEYNOTE756 trial - 1⃣st interim analysis: 💫

✅ Pembro + chemo ⬆️ pCR in high-risk early ER+/HER2− #BreastCancer (24.3% 🆚 15.6%)
⚠️ Manageable safety
📊 EFS data maturing
📰 Read more: nature.com/articles/s41...
@oncoalert.bsky.social

Final OS analysis from #FALCON:

✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC

✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)

@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…

🆕 data from KATHERINE trial confirms T-DM1 improves OS & sustains IDFS in HER2+ early #BreastCancer with residual disease after neoadjuvant therapy.

7-year IDFS: 80.8% (T-DM1) 🆚 67.1% (trastuzumab)
7-year OS: 89.1% (T-DM1) 🆚 84.4% (trastuzumab)

@oncoalert.bsky.social
nejm.org/doi/full/10.10…

Intratumoral💉#pembrolizumab & mRNA-2752 for high-risk #DCIS : Phase 1 nonrandomized trial

✅80% response rate
❌no major systemic toxicities
✅ complete tumor resolution in some➡️possible surgery reduction
🎀 ongoing studies needed
@oncoalert.bsky.social
@jama.com

shorturl.at/W7pU2

Thrilled to share that after an incredible mentorship experience with Prof. Matteo Lambertini last year, I’ve been selected for the 2025 ESO mentorship program!🌟This year, I have the honor of being mentored by Prof. Bostjan Seruga. 🙌
Excited for the journey ahead! 😊😊😊 @oncoalert.bsky.social

⏳Delayed nephrectomy in #mRCC pts with CR/mPR after #immunotherapy shows🍀promising outcomes (48% progression-free at 29.6 months) but comes with ⬆️ surgical complexity - 65.7% cases faced challenges when tumor downsizing >10%.

👉 link.springer.com/article/10.1...

@oncoalert.bsky.social #OncoAlertAF

✨C9741 trial 12-year FU insights in @JCO_ASCO:

Dose-dense chemo shows sustained benefit in N+ #BreastCancer
📈+23% DFS (HR 0.77)
📈+20% OS (HR 0.80)

🔬Low SET2,3 biomarker = biggest benefit in ER+

❌Tumor burden, molecular subtype, menopausal status ≠ predictive

@oncoalert.bsky.social
rb.gy/gyi9jm

🎀January is #CervicalCancerAwarenessMonth🎀

💡 #Prevention saves lives:
✅ #HPV vaccine: Effective protection against the cause
✅ Regular screenings - early detection: PAPA test & HPV test
✅ Treatment of precancerous lesions

@oncoalert.bsky.social
#CervicalCancer #Oncology

🆕Insights from the EUROPA trial🌟in @TheLancet :
In women aged 70+ with low-risk, early #breastcancer, radiotherapy 🆚 endocrine therapy after BCS showed:
🎀Better HRQoL at 24 months (-3.4 vs -9.8, p=0.045)
🎀Fewer adverse events (67% vs 85%)
@oncoalert.bsky.social
thelancet.com/journals/lanon…

Oncology leads the way! 🚀
🧬 In 2024, the FDA approved ✅50 new therapies, with 15 (30%) 🎯targeting cancer – including multiple first-in-class therapies and the 11th PD1/PDL1 inhibitor.
@oncoalert.bsky.social #Oncology #FDAApprovals #Innovation

nature.com/articles/d4157…

🆕
#HELEN006 trial:
weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects.
A potential new standard for neoadjuvant therapy❓
@oncoalert.bsky.social

thelancet.com/journals/lanon…

💫Exciting results from the MECCA Phase III trial: Metronomic capecitabine combined with an aromatase inhibitor significantly improved ✅ PFS and OS in patients with HR+/HER2-negative metastatic breast cancer.
A promising first-line therapy!💫

🖇️ ascopubs.org/doi/10.1200/JC…

@oncoalert.bsky.social

On December 27, 2024, @fda.gov approved ✅ #Subcutaneous nivolumab 💉across approved adult, solid tumor indications, ❌ except in combination with intravenous ipilimumab

www.fda.gov/drugs/resour...

✨✨✨✨✨✨✨✨✨✨✨✨✨
@oncoalert.bsky.social

What happiness and motivation this morning! 🤩🤩🤩
I’ve been selected to participate in Open Medical Institut - #OMI seminar on Breast and Gynecologic Cancers which has been my long-time dream! 🫶🫶🫶